According to our data, anti-CCR7 therapy could also target or avoid CNS infiltration, tackle bulky lymphadenopathies, or prevent T-PLL relapse in settings of minimal residual disease in lymphoid organs or other sites where alemtuzumab is ineffective in tumor cell clearance. Here, CCR7 is linked to Lymphadenopathy.